Compare TransMedics Group Inc (TMDX) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Williams-Sonoma, Inc. — how do they compare? TransMedics Group Inc trades at $86.4 (market cap $3.06B), while Williams-Sonoma, Inc. trades at $228.08 (market cap $26.83B). The key difference: Williams-Sonoma, Inc. is far larger — about 8.8× TransMedics Group Inc's market cap, and Williams-Sonoma, Inc. pays a 1.33% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | WSM | |
|---|---|---|
Market Cap | $3.06B | $26.83B |
Sector | Technology | Consumer Cyclical |
52-Week High | $150.42 | $251.81 |
52-Week Low | $61.99 | $168.64 |
Enterprise Value | $3.46B | $27.33B |
Dividend Yield | — | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Williams-Sonoma (WSM) trades at $227.83, up 0.18% with a bearish technical signal despite strong fundamentals. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $2.10 beating expectations of $2.08. Revenue trends show stabilization around $7.7-8.0B with improving net margins to 14.73%. Technical indicators show the stock testing support at $225 with RSI at oversold levels, suggesting potential near-term bounce.
The outlook remains positive with analyst consensus target of $252.23 representing 10.7% upside. Strong market share gains in home furnishings and raised full-year guidance support bullish case, though tariff pressures and competitive retail environment present ongoing risks. Institutional buying activity, including HSBC's 12.1% position increase, reinforces confidence in the company's execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
